Last Updated:
10 Mar 2026, 03:29:48 PM (IST)
Kilitch Drugs (India) Limited
NSE: KILITCH BSE: KILITCH
NSE
316.75
-3.40 (-1.06%)
Prev Close
320.15
Open Price
324.8
Volume
22,594
Today Low / High
315 / 324.8
52 WK Low / High
299.95 / 500
Range
301 - 333
BSE
320.00
-0.10 (-0.03%)
Prev Close
320.1
Open Price
328.1
Volume
2,873
Today Low / High
317 / 328.1
52 WK Low / High
271.3 / 500.05
Range
304 - 336
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 316.75 (target range: 301 - 333), reflecting a change of -3.4 (-1.062%). On the BSE, it is listed at 320 (target range: 304 - 336), showing a change of -0.1 (-0.03124024%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Kilitch Drugs (India) Limited Graph
Kilitch Drugs (India) Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Kilitch Drugs (India) Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 316.75, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 320.00 | 323.20 | 290.88 - 355.52 |
| 326.40 | 261.12 - 391.68 | ||
| 329.60 | 230.72 - 428.48 | ||
| Bearish Scenario | 320.00 | 316.80 | 285.12 - 348.48 |
| 313.60 | 250.88 - 376.32 | ||
| 310.40 | 217.28 - 403.52 |
Overview of Kilitch Drugs (India) Limited
ISIN
INE729D01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
16,038
Market Cap
5,547,526,168
Last Dividend
0
Official Website
IPO Date
2010-09-29
DCF Diff
483.85
DCF
-162
Financial Ratios Every Investor Needs
Stock Dividend of KILITCH
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2019-09-20 | September 20, 19 | 0.5 | 0.5 | 2019-09-23 | 2019-10-30 | 2019-05-30 |
| 2018-09-18 | September 18, 18 | 0.5 | 0.5 | 2018-09-19 | 2018-10-27 | 2018-05-25 |
| 2012-09-24 | September 24, 12 | 30 | 30 | 2012-09-25 | 2012-09-29 | 2012-08-30 |
| 2011-08-18 | August 18, 11 | 1 | 1 | 2011-08-22 | 2011-10-10 | 2011-07-25 |
| 2010-10-14 | October 14, 10 | 1 | 1 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 198.32 Cr | 104.58 Cr | 93.74 Cr | 0.4727 | 0.00 Cr | 11.32 Cr | 28.35 Cr | 26.70 Cr | 16.24 | 42.63 Cr | 0.1346 |
| 2024-03-31 | 153.61 Cr | 80.47 Cr | 73.14 Cr | 0.4761 | 0.00 Cr | 3.76 Cr | 21.11 Cr | 14.60 Cr | 8.97 | 28.74 Cr | 0.0951 |
| 2023-03-31 | 139.60 Cr | 77.13 Cr | 62.46 Cr | 0.4475 | 0.00 Cr | 1.99 Cr | 14.86 Cr | 10.45 Cr | 6.57 | 20.65 Cr | 0.0748 |
| 2022-03-31 | 114.23 Cr | 80.49 Cr | 33.74 Cr | 0.2954 | 0.00 Cr | 1.95 Cr | 8.99 Cr | 7.37 Cr | 4.63 | 13.41 Cr | 0.0645 |
| 2021-03-31 | 68.13 Cr | 38.12 Cr | 30.01 Cr | 0.4404 | 0.00 Cr | 2.15 Cr | 3.62 Cr | 3.67 Cr | 2.37 | 7.98 Cr | 0.0539 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 9.80 Cr | 312.78 Cr | 112.33 Cr | 202.3291 Cr | 49.42 Cr | 39.62 Cr | 15.31 Cr | 92.82 Cr | 0.00 Cr | 0.00 Cr | 22.86 Cr | 84.3101 Cr |
| 2024-03-31 | 18.91 Cr | 240.06 Cr | 64.39 Cr | 176.2912 Cr | 31.65 Cr | 12.74 Cr | 9.31 Cr | 48.12 Cr | 0.00 Cr | 0.00 Cr | 22.85 Cr | 64.2159 Cr |
| 2023-03-31 | 19.85 Cr | 219.52 Cr | 68.94 Cr | 151.5972 Cr | 22.19 Cr | 2.35 Cr | 2.41 Cr | 47.36 Cr | 0.00 Cr | 0.00 Cr | 22.68 Cr | 68.8731 Cr |
| 2022-03-31 | 10.01 Cr | 209.85 Cr | 69.55 Cr | 139.0864 Cr | 20.43 Cr | 10.42 Cr | 5.29 Cr | 46.40 Cr | 0.00 Cr | 0.00 Cr | 26.07 Cr | 69.2792 Cr |
| 2021-03-31 | 12.45 Cr | 203.18 Cr | 73.70 Cr | 127.1287 Cr | 14.80 Cr | 2.36 Cr | 3.59 Cr | 73.38 Cr | 0.00 Cr | 0.00 Cr | 25.65 Cr | 73.3162 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 17.5423 Cr | -39.9469 Cr | 13.2433 Cr | -29.3311 Cr | -9.1613 Cr | 9.8005 Cr | -46.8734 Cr | 34.4743 Cr | 17.7775 Cr | 0.0000 Cr | -11.3216 Cr |
| 2024-03-31 | -0.1463 Cr | -9.5447 Cr | 8.8067 Cr | -6.5967 Cr | -0.8842 Cr | 18.9618 Cr | -6.4504 Cr | 19.3545 Cr | 9.4529 Cr | 0.0000 Cr | -1.9434 Cr |
| 2023-03-31 | 2.5858 Cr | 7.9150 Cr | -0.7163 Cr | -1.2261 Cr | 9.7845 Cr | 19.8460 Cr | -3.8119 Cr | 12.0143 Cr | 1.7617 Cr | 0.0000 Cr | 2.9556 Cr |
| 2022-03-31 | 5.7830 Cr | -15.2504 Cr | 7.0283 Cr | -2.4188 Cr | -2.4390 Cr | 10.0615 Cr | -8.2018 Cr | 9.6144 Cr | 5.6281 Cr | -1.1984 Cr | -1.4141 Cr |
| 2021-03-31 | 45.6589 Cr | -37.5692 Cr | 1.6142 Cr | 9.3610 Cr | 9.7039 Cr | 12.5005 Cr | -36.2979 Cr | 5.1196 Cr | 2.1946 Cr | 0.0000 Cr | 1.9706 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 53.81 Cr | 35.33 Cr | 18.48 Cr | 0.3434 | 5.21 Cr | 4.43 Cr | 2.54 | 6.15 Cr | 0.0824 |
| 2025-09-30 | 48.92 Cr | 30.98 Cr | 17.94 Cr | 0.3667 | 4.18 Cr | 8.19 Cr | 4.97 | 11.70 Cr | 0.1674 |
| 2025-06-30 | 43.14 Cr | 25.46 Cr | 17.68 Cr | 0.4098 | 2.42 Cr | 3.03 Cr | 1.84 | 5.82 Cr | 0.0701 |
| 2025-03-31 | 61.23 Cr | 28.70 Cr | 36.09 Cr | 0.5894 | 14.13 Cr | 10.40 Cr | 6.34 | 16.67 Cr | 0.1699 |
| 2024-12-31 | 56.17 Cr | 32.76 Cr | 23.41 Cr | 0.4167 | 7.93 Cr | 5.96 Cr | 3.63 | 10.46 Cr | 0.1061 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 33.09 Cr | 53.92 Cr | 87.01 Cr | 92.91 Cr | 13.01 Cr | 209.33 Cr | 143.10 Cr | 398.66 Cr | 134.48 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 59.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -200.46 Cr |
| 2025-03-31 | 9.80 Cr | 49.60 Cr | 59.40 Cr | 84.74 Cr | 15.31 Cr | 173.92 Cr | 92.82 Cr | 312.78 Cr | 112.33 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 58.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -188.48 Cr |
| 2024-09-30 | 5.33 Cr | 52.58 Cr | 58.87 Cr | 71.47 Cr | 5.13 Cr | 147.67 Cr | 65.91 Cr | 259.43 Cr | 70.95 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 3.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 10.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 5.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 8.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2025-07-15 | July 15, 25 | 1021:1000 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Whole-time Director
Bhavin Mukund Mehta
Gender: male
Year Born: 1976
Executive Chairman & MD
Mukund Prataprai Mehta
Gender: male
Year Born: 1953
Chief Financial Officer
Sunil Sureshji Jain
Gender: male
Year Born: 1983
MD & Director
Mira Bhavin Mehta
Gender: female
Year Born: 1978
Company Secretary & Compliance Officer
Pushpa Nyoupane
Gender: female
Year Born:
General Manager - Administration
Rajesh Khatri
Gender: Not Specified
Year Born: 1975
VP-Marketing & Operation
Tajouddin Ansari
Gender: Not Specified
Year Born:
FAQs about Kilitch Drugs (India) Limited
Who is the CEO of the company?
The CEO is Mukund Prataprai Mehta.
What is the current market price of the stock?
The current price is ₹317.35.
What is the 52-week price range?
The range is ₹299.95-500.
What is the market capitalization of the company?
The market capitalization is ₹554.75 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 21.30.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Kilitch Drugs (India) Limited (ISIN: INE729D01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹554.75 crores and an average daily volume of 16,038 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.